Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,221 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Arterial Occlusive Disease Clear all

Conditions: Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions: cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 11,145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Anderson, South Carolina

Conditions: Heart Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 95 Years
Enrollment: 5,302 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2004
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Atherosclerosis, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Hypertension
Interventions: Not listed
Lead sponsor: Tulane University; Other
Eligibility: Not listed
Enrollment: 11,737 participants
Timeline: 1973 – 2040
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Ischemia
Interventions: Harvest Smartprep2 BMAC System, SmartPReP2 BMAC System, placebo; Device · Biological
Lead sponsor: Harvest Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 6
States / cities: Tampa, Florida • Boston, Massachusetts • Albany, New York + 3 more

Conditions: Cardiovascular Disease
Interventions: Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Total Occlusion of Coronary Artery, Angina Pectoris, Quality of Life, PROM
Interventions: Chronic total occlusion(CTO) percutaneous coronary intervention (PCI); Procedure
Lead sponsor: Haukeland University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension and Coronary Artery Disease
Interventions: Celecoxib, placebo; Drug
Lead sponsor: University of Florida; Other
Eligibility: 50 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Gainesville, Florida • Houston, Texas

Conditions: Angioplasty, Chronic Coronary Occlusion, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions: XIENCE V® Everolimus Eluting Coronary Stent System (EECSS); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 2,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Santa Clara, California

Conditions: Peripheral Arterial Occlusion or Emboli
Interventions: Mechanical Thrombectomy by the Indigo System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: San Diego, California • Miami, Florida • Chicago, Illinois + 2 more

Conditions: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Background care, Placebo, dalcetrapib; Other · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 45 Years and older
Enrollment: 2,220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 121
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anaheim, California + 112 more

Conditions: Peripheral Arterial Disease
Interventions: Bupivacaine liposome, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Eau Claire, Wisconsin

Conditions: Coronary Artery Disease
Interventions: Bioresorbable Vascular Scaffold, Drug Eluting Stent; Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Stroke, Ischemic, Intracranial Atherosclerosis, Posterior Circulation Brain Infarction
Interventions: we are aiming to develop a Scoring system based on certain variables derived from both groups; Other
Lead sponsor: Sohag University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions: Hydroxychloroquine, Matching Placebo; Drug · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida

Conditions: Coronary Artery Disease
Interventions: The Multi-vessel Coronary Artery Disease Option Grid, Usual Care; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Portland, Maine • Lebanon, New Hampshire • Albany, New York

Conditions: Coronary Artery Disease, Ischemia
Interventions: Computed Tomography Angiography; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atherosclerosis
Interventions: Rosuvastatin 10 mg, Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Pulmonary Artery Stenosis
Interventions: PALMAZ MULLINS XD™ Pulmonary Stent; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Sacramento, California • Atlanta, Georgia • Detroit, Michigan + 5 more

Conditions: Memory Disorders, Alzheimer's Disease
Interventions: Aricept, IFN-alpha2A; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Peripheral Arterial Disease
Interventions: Advanta VXT Vascular Graft, Flixene Vascular Graft; Device
Lead sponsor: Atrium Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fall, Fall Injury, Peripheral Artery Disease, Peripheral Arterial Disease
Interventions: Adapted Otago Exercise Program (OEP); Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions: CGT003 (E2F Duplex Decoy); Drug
Lead sponsor: Anesiva, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 116
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Coronary Artery Disease
Interventions: PB127 for injectable suspension; Drug
Lead sponsor: Point Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 19
States / cities: Scottsdale, Arizona • San Francisco, California • Stanford, California + 14 more

Conditions: Peripheral Arterial Disease(PAD)
Interventions: Not listed
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Shreveport, Louisiana

Search by objective public record fields.

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Identifying Genes That May Increase the Risk for Heart Disease in African Americans

Bogalusa Heart Study

Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)

Dose-dependent Effects of Second-hand Smoke on Vascular Function

Invest-CTO PCI Trial

Effect of Celecoxib on Markers of Vascular Inflammation

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study

Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

A Study of Loco-Regional Liposomal Bupivacaine Injection

Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds

Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

Treatment Decisions for Multi-vessel CAD

Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

Post-Approval Study of PALMAZ MULLINS XD™ in Treating Pulmonary Artery Stenosis

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Advanta VXT and Flixene PMCF Registry

Integrating Fall Prevention Balance Exercises Into a Program for Older Adults With Peripheral Artery Disease (PAD): A Mixed Methods Feasibility Study

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007

Ankle-Brachial Index Changes Post Exercise and Its Effects on Patient-Centered Outcomes and Gait